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Abstract
Spontaneous tumor regression is a unique feature of
pediatric low-grade gliomas (PLGG). We speculated
that lack of telomere maintenance is responsible for
this behavior. We first looked for evidence of telo-
merase activity and alternative-lengthening telomeres
(ALT) in 56 PLGG. Telomerase activity was observed
in 0 of 11 PLGG in contrast to 10 of 13 high-grade pe-
diatric brain tumors. There was no ALT in 45 of 45 sam-
ples. We applied Q-FISH to eight patients whose
indolent PLGG underwent two metachronous biopsies
over a lag of several years. Telomere shortening was
observed in the second biopsy in all tumors but not in a
normal brain control (P < .0001), indicating that lack of
telomere maintenance is associated with continuous
telomere erosion. Based on these observations, we
observed that younger PLGGpatientswho exhibit more
aggressive and frequently recurrent tumors had sig-
nificantly longer telomeres than older ones (P = .00014).
Tumors with a terminal restriction fragment length of
<7.5 did not recur, whereas the presence of longer
telomeres (>8.0) conferred a high likelihood of late
recurrences in PLGG. Our findings provide a plausible
biological mechanism to explain the tendency of PLGG
to exhibit growth arrest and spontaneous regression.
Telomeremaintenancemay therefore represent the first
known biologic prognostic marker in PLGG.
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Introduction
Central nervous system neoplasms constitute the most
common solid tumors of childhood. Although there has been
great improvement in the treatment and outcome of most
pediatric tumor types, this is not the case for most pediatric
brain tumors (PBT). Currently, PBT are the major cause of
mortality and long-termmorbidity in pediatric oncology. PBTare
a heterogeneous group of tumors. Some, such as high-grade
gliomas, have a relentless and aggressive course. Others, such
as pediatric low-grade gliomas (PLGG), exhibit erratic behavior
ranging from aggressive and recurrent growth to prolonged
phases of stable disease and, rarely, a striking tendency to
spontaneously regress [1]. In contrast to adults, in whom low-
grade gliomas tend to eventually progress or transform to high-
grade gliomas [2,3], this phenomenon is extremely rare in the
pediatric population, suggesting a different biologic basis. Cur-
rently, there are no plausible explanations for the tendency of
certain PLGG to exhibit behaviors such as spontaneous invo-
lution. In the pediatric age group, two other potentially malignant
diseases tend to spontaneously regress or arrest growth. These
are stage IVS neuroblastoma [4] and transient myeloprolifera-
tive disease (TMD) in infants with Down syndrome [5]. Recently,
it has been suggested that lack of telomere maintenance in
these tumors is responsible for their self-limiting nature.
Telomeres are unique structures located at the terminal
ends of each chromosome. They function as a cap that protects
the ends of the DNA double helix from being exposed and
recognized as DNA breaks. During each mitotic cycle, a por-
tion of the telomere is lost. Continued telomere shortening
ultimately results in a growth-arrested state known as cellular
senescence [6]. Telomerase is a ribonucleoprotein that cata-
lyzes the cellular synthesis of telomeric DNA, resulting in
maintenance of telomere length and increased proliferative
potential. Telomerase activity is normally found only in stem
cells and not in most normal somatic cells [7]. Unfortunately,
more than 85% of all malignant human cancers and almost
100% of advanced cancers tested to date express high levels of
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telomerase [8]. Aminority of tumors utilize a differentmethod,
termed ALT, to escape senescence [9]. Telomerase is not
active in TMD patients as opposed to their counterparts who
evolve to acute myeloid leukemia, in which high levels of
telomerase activity have been found [10]. Others have dem-
onstrated that advanced-stage neuroblastoma exhibited
significantly more telomerase activity than stage IVS tumors
[11,12]. The unpredictable behavior, spontaneous growth
arrest, and regression of PLGG make them attractive candi-
dates for the study of telomeremaintenance and senescence
and for possible exploitation of these features for prognosti-
cation and novel treatment options.
The primary aim of this study was to determine whether
telomere maintenance is lacking in PLGG and to correlate
this phenomenon with telomere shortening. A secondary
objective was to utilize telomere length in PLGG as a prog-
nostic marker for clinical use.
Methods
Tissue and Patient Accrual
Patient samples used in this study were obtained from
archival biopsies of PLGG performed at The Hospital for
Sick Children (Toronto, Canada) (Table 1). The study was
approved by the hospital’s Research Ethics Board. Protein
was extracted from 11 frozen tissues of PLGG (Table 1) and
13 high-grade brain tumors for polymerase chain reaction–
enzyme-linked immunosorbent assay (PCR-ELISA) telome-
rase assay. Although 24 patients who had had two sequential
biopsies over a significant lag period were initially identified,
16 were excluded from study because they had received
therapy between the two biopsies, and 2 were excluded due
to lack of sufficient tissues for analysis. For telomere length
assays, formalin-fixed and paraffin-embedded tissues from
16 PLGG (two sequential biopsies from each of eight pa-
tients) and two normal brain control were used for quantita-
tive fluorescence in situ hybridization (Q-FISH). For each
specimen, serial 5-mm sections were obtained from the
blocks. Hematoxylin and eosin (H&E) staining was used to
identify the regions of interest, and the same samples were
used for immunohistochemistry studies. DNA was extracted
from frozen tissues of a separate set of 45 PLGG for the
terminal restriction fragment (TRF) assay. As noted in
Table 1, each tumor sample was used only for one assay;
thus, no two tests were performed on the same tumor. For
prognostication and risk stratification analysis, demographic,
pathological, and clinical follow-up data were obtained for
PLGG patients through the neuro-oncology database and
medical chart reviews.
Telomerase Assay
Tissue extraction and PCR-ELISA were performed ac-
cording to the Telomerase PCR-ELISA kit (Roche Diag-
nostics, Mannheim, Germany), as previously described [12].
Briefly, a fragment of frozen tumor tissue was homogenized
in lysis buffer and centrifuged, and the supernatant was re-
moved. Protein concentration was determined using the Pro-
tein Assay ESL Kit (Roche Diagnostics). For each sample, a
negative control was created by incubation with RNase at
37jC for 20 minutes. To identify false-negative tumor sam-
ples, a spiked sample containing both tumor lysate and posi-
tive control was also created for each specimen. The test
positive control consisted of 2 ml of supplied positive control
solution; the test negative control consisted of 5 ml of lysis
buffer added to the reaction mixture. These samples were
then incubated at 25jC. Next, telomerase was inactivated by
heat treatment, and the reaction mixtures then underwent
30 PCR cycles of 94jC for 30 seconds, 50jC for 30 seconds,
and 72jC for 90 seconds. On completion of the PCR proto-
col, denaturation and hybridization were performed accord-
ing to the kit protocol. The samples were read on a Titretek
Multiskan MCC/340 microtiter plate reader at 450 nm with
a reference wavelength of 690 nm. Test results were ex-
pressed as the A450 nm against the blank (A690 nm). The test
negative control was accepted if the maximum absorbance
A450–690 nm = 0.25. The test positive control was considered
valid if absorbance was A450–690 nm z 1.5. Samples were
regarded as telomerase-negative if A450–690 nm = 0.2. They
were regarded as weakly positive if A450–690 nm = 0.2 to 0.5
and as strongly positive if A450–690 nm > 0.5. RNA quality was
determined for specimens that were negative or weakly posi-
tive on telomerase assay.
Q-FISH
Q-FISH was performed using pan-telomeric and pan-
centromeric peptide nucleic acid (PNA) probes on unstained
5-mm paraffin sections. Telomere (C3TA2)3–specific and
Table 1. Distribution and Subtypes of PLGG Used for Different Assays.
Assay Pathology n Location Remarks
TRAP assay Grade 1 7 Posterior fossa 13 High-grade brain tumors used as controls
Grade 2 4
Q-FISH + immunohistochemistry Grade 1 16 Posterior fossa Normal brain from epilepsy surgery
Normal brain 2 Temporal lobe
TRF—age groups Grade 1 19 Posterior fossa Equally distributed between groups
Grade 2 6
TRF—time to last progression Grade 1 15 Optic pathway Unresectable tumors
Grade 2 2 Brainstem
Ganglioglioma 2 Spinal cord
Pleomorphic xanthoastocytoma 1
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centromere (16-mer repeat DNA)–specific probes directly
labeled with Cy3 and fluorescein isothiocyanate (FITC) fluo-
rescent dyes, respectively, were obtained from Applied Bio-
systems (Foster City, CA). The sequences of these are as
follows: Flu-OEE-ATT-CGT-TGG-AAA-CGG-GA-EE; Flu-
OEE-CAC-AAA-GAA-GTT-TCT-GAG-EE; Flu-OEE-CAG-
ACA-GAA-GCA-TTC-TCA-EE; and Flu-OEE-TGC-ATT-
CAA-CTC-ACA-GAG-EE. We used a standard technique
for PNA FISH [13], with some modifications. Briefly, the
sections were deparaffinized in xylene and dehydrated with
100% EtOH. Slides were incubated with 100 g/ml RNase in
2 SSC at 37jC for 60 minutes, washed with 2 SSC for
2minutes, and treatedwith 1MNaSCN for 8minutes at 80jC.
After washingwith deionizedH2O, the sectionswere digested
in 5 mg/ml pepsin solution in 0.6% NaCl (pH 1.5) for 10 min-
utes at 45jC and rinsed in 2 SSC at room temperature for
5 minutes. Slides were further treated with 0.1 M triethanol-
amine, rinsed with 1 PBS and 2 SSC for 10 minutes,
dehydrated through an ethanol series (70%, 90%, and
100%), and air-dried. A mixture of 2 ml of the telomeric and
centromeric probes was then applied to the sections to give a
final probe concentration of 0.5 g/ml in each case. Coverslips
were placed on areas of interest and sealed with rubber
cement. Slides were denatured on a preheated block, trans-
ferred to a humidified chamber, and hybridized in the dark for
1 hour at 25jC. Coverslips were then removed, and the slides
were washed in formamide solution for 15 minutes followed
by three washes in Tween solution. Slides were counter-
stained with DAPI antifademixture (Vectashield, Burlingame,
CA) and analyzed. Only tissue sections with a hybridization
efficiency of >95% were included in the study, having been
previously validated and standardized by our group.
Image Capture
Regions of interest were determined on parallel H&E
sections and identified on FISH slides using DAPI channel
to minimize exposure in the Cy3 and FITC channels. Slides
were then analyzed with a Zeiss Axiophot II epifluorescence
microscope (Zeiss, Toronto, Canada) equipped with a mer-
cury lamp and a 100 1.4 NA oil immersion lens. Images
were captured using a CCD camera and Isis FISH imaging
software (Metasystems GmbH, Altlussheim, Germany). To
compensate for cell thickness, three consecutive images at
different focal depths (average of 1 mm separation) were
stacked into a composite image used for quantitation. Bleach-
ing effects due to repeated exposure of a selected area during
image capture were assessed, and an intensity loss of 1%
was found between exposures. Exposure times were opti-
mized with respect to the intensities of telomere and centro-
mere signals to prevent overexposure saturation of the
signals in the original and stacked images. Once determined,
they were kept constant for all slides per patient to ensure
consistency in intensity measurements. For each slide, its
paired biopsy served as a control to ensure that there would
be no variation in fluorescence due to the pretreatment
protocol. An average of 25 cells was examined on adjacent
sections to quantify the telomeric and centromeric signals
using Q-FISH on each of the 20 specimens (10 patients).
Image Analysis
Quantitative analysis of telomere/centromere signal inten-
sities was performed on captured images and used to deter-
mine relative changes in telomere length and DNA ploidy.
Original eight-bit images of each channel were exported from
Metasystems GmbH into Adobe Photoshop, where cell bor-
ders were defined based on DAPI nuclear outline. Images of
individual nuclei were then exported and analyzed quantita-
tively using ImageJ software. Quantitative analysis was
performed (on a per-nucleus basis) on Cy3 and FITC images
using a simple thresholding function to outline the signals.
The intensities of all pixels outlined by the threshold were
summed up on a per-cell basis and tabulated. Because ploidy
changes are sometimes observed in PLGG, all telomere
intensities were expressed as a telomeric-to-centromeric
signals ratio for each nucleus. Centromeric intensities were
used as a measure of gross ploidy changes. Telomeric ratios
and centromeric intensities were then averaged between
cells from each surgery and compared using analysis of
variance (ANOVA) in Excel followed by Student-Newman-
Keuls (SNK) test.
TRF Assay
Telomere lengths were determined by a TRF kit (Roche
Diagnostics). Briefly, extracted DNA samples (1–2 mg of
tumor DNA) were digested with the restriction enzymes RsaI
and Hin fI at 37jC for 2 hours and run on 0.8% agarose gels
at 10 V for 18 hours. A biotinylated gamma DNA molecular
weight marker was used as DNA length standard. High- and
low-molecular-weight DNA were run as positive controls.
The DNA samples were depurinated in 0.25 M HCl, dena-
tured in 0.4 M NaOH/3 M NaCl, and transferred to a posi-
tively charged nylon membrane Hybond-N (Amersham
Pharmacia Biotech, Little Chalfont, England, UK) by capillary
blotting over 12 hours. The membrane was washed in sa-
line–sodium citrate buffer. The blot was hybridized with a
(TTAGGG)3 telomere probe at 42jC for 3 hours and washed
in 2 SSC/0.1% sodium dodecyl sulfate. Chemiluminescent
detection was performed according to the Detection Kit
(Roche Diagnostics). Detection was performed on an X-ray
Hyperfilm ECL. To address the issue of tissue heteroge-
neity, mean TRF lengths were calculated as e(ODi)/e(ODi/
Li). The final number represents the mean molecular size of
36 equal intervals of telomeric smears in the range of 2 to
20 kb, as defined by DNA length standard. ODi reflects the
measured intensity of luminescence in each of the 35 inter-
vals. As reported in the literature, TRF lengths were recorded
as telomere lengths.
Immunohistochemistry for TP53, Caspase-3, and p16
Five-micrometer sections were cut from the tissues used
for the Q-FISH assay and mounted on positively charged
microscope slides. Tissue sections were then baked over-
night at 60jC, dewaxed in xylene, and hydrated with dis-
tilled water through decreasing concentrations of alcohol.
Immunohistochemical procedures for antibodies against
p53 (clone DO-7; Dako Cytomation, Mississauga, Canada),
cleaved caspase-3 (Asp175; Cell Signaling Technology,
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Denvers, MA), and p16 (clone G175-405; BD Pharmingen,
Franklin Lakes, NJ) at dilutions of 1:20, 1:25, and 1:10,
respectively, were performed on Ventana NEXES autoimmu-
nostainer (Ventana Medical Systems, Tucson, AZ) with a
closed avidin–biotin complex method system using the 3,3-
diaminobenzidine Ventana Detection System. All tissue sec-
tions were treated with heat-induced epitope retrieval and
blocked for endogenous peroxidase and biotin. The counter-
stain of preference was hematoxylin. Appropriate positive and
negative controls were also performed in parallel for each
immunostain.
Statistical Analysis
To determine whether the reduction in telomeric signals
was statistically significant, ANOVA was performed, followed
by SNK test. Thirty cells were analyzed for each surgery. Each
cell was recorded at three different nuclear vertical layers.
The average of the ratio between telomeric and centromeric
intensities was recorded. Analysis was performed per patient
by comparing the first surgery to the second one. For telo-
mere length/age analysis, Student’s t test was applied.
Results
Lack of Telomere Maintenance in PLGG
Telomerase activity was noted in 0 of 11 PLGG, in contrast
to 10 of 13 pediatric high-grade tumors (P = .013) (Table 2).
None of the 45 samples analyzed using TRF demonstrated
abnormal telomere elongation (Figure 3B shows eight rep-
resentative samples) or a highly heterogeneous distribution
of telomere length, indicating lack of ALT in PLGG. U-2OS
and Saos-2 osteosarcoma cell lines were used as positive
controls (data not shown).
Telomere Shortening in Progressive PLGG
To evaluate progressive telomere shortening, we used
paraffin sections from biopsies of eight PLGG patients and
one normal brain control who underwent two surgical proce-
dures over a lag of several years (mean, 3.7 years; SD,
1.5 years) and in whom neither chemotherapy nor radiother-
apy had been used as part of treatment. Q-FISH was applied
to these samples, as previously described by our group
(Figure 1) [13]. Lower telomere-to-centromere intensity ratios
were found in the second tumor resection when compared
with the first in all eight patients (P < .001) (Figure 2),
indicating progressive telomere shortening over time in
PLGG. In the normal brain control taken from a normal brain
adjacent to lesions excised in two sequential epilepsy sur-
geries, no significant change in telomeric-to-centromeric ratio
was noted between the first and second surgery (lag time,
4.5 years). Analysis of telomeric and centromeric intensities
separately revealed a significant reduction in telomere inten-
sities, whereas analysis of pan-centromeric probe revealed
no significant changes between surgeries, indicating a lack of
significant ploidy changes in these tumors (data not shown).
Immunostaining for Apoptosis and Senescence Markers
in PLGG
Adult low-grade gliomas acquire abnormalities in the TP53
and p16 pathways as they progress. To define the role of
these pathways and apoptosis in PLGG that persist over
time, we stained the samples of the eight indolent PLGG that
exhibited telomere shortening for TP53, p16, and cleaved
caspase 3. A total of 18 sampleswas analyzed including eight
primary and recurrent tumors and one normal brain control.
Aberrant expression of TP53 was not noted in any of the
samples. Cleaved caspase 3 showed rare cellular positivity
in only 2 of 18 samples and was not expressed in normal
Figure 1. Q-FISH images from two sequential biopsies of a patient with a pilocytic astrocytoma. FISH with centromeric (FITC; green) and telomeric (Cy3; red) PNA
probes on paraffin-embedded recurrent PLGG. DAPI was used as a counterstain with 100 (left) and 10 (middle) objectives. Identical images in black and white
(right) with nuclei outlined in gray and telomere signals represented by dark spots. Red dots represent telomeres, and green dots represent centromeres.
Table 2. Telomerase Activity, Measured by PCR-ELISA Technique, in
Pediatric Low-Grade Astrocytomas and High-Grade Brain Tumors.
Tumor Tested (n) Positive (n)
Low-grade
Astrocytoma 11 0
High-grade
Anaplastic astrocytoma 4 2
PNET/medulloblastoma 7 6
Anaplastic ependymoma 2 2
Telomere Maintenance in Pediatric Low-Grade Gliomas Tabori et al. 139
Neoplasia . Vol. 8, No. 2, 2006
brain controls. p16 revealed a variable degree of cytoplasmic
and perinuclear staining and rare nuclear staining (1–20% of
cells) in 15 of 16 tumor samples, but not in normal brain tis-
sue (data not shown).
Telomere Length as a Prognostic Marker in PLGG
To determine the significance of telomere length as a
prognostic marker in PLGG, we studied known risk groups
and patients with prolonged long-term follow-up. In total,
45 PLGG were analyzed for TRF. Telomeres were longer
in young patients (<4 years, n = 12) than in older ones
(>10 years, n = 13) (P = .00014; Figure 3A), which correlates
with the tendency of young patients to have a more prog-
ressive course than older ones [14,15]. Because lack of telo-
mere maintenance may promote PLGG to senescence, we
assessed the correlation between telomere length and the
propensity of tumors to eventually cease growing. We mea-
sured telomere length in unresectable optic pathway, exo-
phytic brainstem, and spinal cord PLGG cases (Table 1) who
were followed for more than 2 years (mean time, 4.56 years;
SD, 2.06). For each patient, time to last progression was
determined as tumor survival characteristic (Figure 4).
Tumors with mean telomere length (TRF) of <7.5 did not
progress (n = 4). Patients with TRF of <8 did not progress
more than 2 years after diagnosis (n = 5), whereas tumors
with longer telomeres (n = 11) continued to progress up to
7 years from diagnosis. These findings further reinforce the
correlation between continuous telomere erosion and spon-
taneous senescence in PLGG.
Discussion
Tumorigenesis is associated with acquisition of an immortal
phenotype that requires telomere maintenance [16]. Several
other alterations in cell regulation can cause malignant trans-
formation. However, to sustain the ability to continue indefi-
nite proliferation, cancer cells must reactivate telomerase
or utilize ALT. Lack of this ability will not permit a fully ma-
lignant phenotype. Although this mechanism has been
Figure 3. TRF measurement for subgroups of PLGG patients. (A) Mean TRF
length in patients younger than 4 years (n = 12) and older than 10 years
(n = 13). (B) TRF analysis of PLGG in younger and older patients. Note the
longer mean TRF for younger patients.
Figure 2. Q-FISH analysis of telomere length. The y-axis represents telomere divided by centromere fluorescent intensity. Telomere intensity was reduced in the
second surgery as compared to the first surgery in all patients, but not in the normal brain control. P value was calculated for 30 cells from the first tumor biopsy
compared with the same number from the second tumor biopsy, per patient.
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demonstrated in laboratory in vitro systems, data are lacking
in the clinical setting to correlate lack of telomere mainte-
nance, telomere shortening, and clinical course.
In this study, we have shown for the first time a correlation
between lack of telomere maintenance and progressive
telomere shortening in pediatric tumors. Because biopsies
are not performed on tumors that regress, it is impossible to
prove a direct correlation between telomere erosion and
senescence in active tumors. Due to their indolent course,
study of the eight PLGG for which two sequential biopsies
were performed enabled us to demonstrate telomere ero-
sion over time. It is important to note that none of these pa-
tients died and that these persistent tumors were treated
successfully with surgery, indicating that telomere shorten-
ing was not associated with a more biologically aggressive
tumor behavior. Data from a larger set of patients in our
study showed a correlation between PLGG with longer
telomeres and the ability to progress for many years, as op-
posed to lack of progression in PLGG with shorter telo-
meres (Figure 4). These data further support our hypothesis.
Most cancer cells adopt mechanisms to evade cell death
through alterations in major apoptotic pathways. However,
senescence, if reached through progressive telomere ero-
sion, may explain the slow growth and involution of some
tumor subtypes, including PLGG. Our understanding of the
role of senescence in cancer is still rudimentary. Although
our observations allow us to better understand the unique
clinical behavior of PLGG, they also offer a wider view of
the role of telomere maintenance and senescence in tumori-
genesis. Many tumors such as colon, prostate, and breast
cancers are thought to originate in premalignant lesions in
which telomeres are longer [13,17] and telomerase is not
active. However, up to 90% of malignant neoplasms exhibit
telomerase activity [8], implying that telomerase is reacti-
vated in later stages of tumorigenesis. This feature has been
shown to worsen the prognosis of glioblastomas [18,19] and
colon carcinomas [20,21], whereas evidence of ALT confers
better prognosis for these cancers and some pediatric sar-
comas [22]. Development of approaches to prevent cells from
possibly reactivating telomerase may serve as a fundamen-
tal step in the prevention of malignant transformation [23].
The striking contrast between lack of telomere mainte-
nance and the tendency of PLGG to exhibit growth arrest, on
one hand, and the relentless progression of adult LGG to
high-grade tumors while reactivating their telomerase or
using ALT [18,19], on the other hand, points to fundamentally
different biologic mechanisms. Furthermore, lack of aberrant
TP53 expression and the intact expression of p16 in PLGG
suggest that these pathways are intact in PLGG as opposed
to LGG in adults, where alterations in these pathways are
common in the progression of LGG to high-grade astro-
cytomas [24,25]. p16 is involved in senescence, whereas
caspase 3 is a marker for apoptosis. Therefore, expression
of p16 and lack of caspase 3 expression in our indolent
tumors support the role of senescence—not apoptosis—in
PLGG. Although we did not look for mutations in TP53, lack
of TP53 immunostaining is consistent with expression of
wild-type TP53 and has been previously shown to correlate
well with the presence of normal TP53 alleles and favorable
outcomes in these tumors [25,26]. Therefore, our findings
provide a system that might be exploited to control tumor
progression in adult gliomagenesis.
As a consequence of our initial observations, in the sec-
ond part of our study, we explored the use of telomere length
as a prognostic marker for PLGG. Currently, there are no
reliable biologic markers for predicting the behavior of these
tumors. Furthermore, whereas the diagnosis of high-grade
glioma carries poor prognosis, histologically similar PLGG
can have different recurrence rates. Our results, therefore,
are intriguing. Telomere length was significantly longer in
infants and young children, a group that is generally associ-
ated with a more protracted and recurrent clinical course
[14,27]. PLGG with a TRF of <7.5 did not recur or progress,
whereas tumors with longer telomeres possessed the ability
to progress for many years (Figure 4). The possible clinical
implication of this observation is crucial because there is a
trend to delay radiation therapy in these young patients by
administration of chemotherapy. The ability to predict which
of the tumors may spontaneously cease growing and not
require radiotherapy is, therefore, imperative. These latter
findings, although based on a large sample size, should be
interpreted with some degree of caution because the pa-
tients were analyzed retrospectively and had undergone
different treatment regimens that may have influenced out-
come. Nevertheless, we believe that this observation will
serve as the basis for the incorporation of these biologically
relevant factors into future prospective controlled trials.
Telomere length is a novel method used to assess the risk
of tumor progression and recurrence, especially when telo-
merase is not active. This may be true for PLGG but also for
other tumors. Indeed, Gertler et al. [20] found a surprising
correlation between longer telomeres and more aggressive
colon carcinomas. They speculated that continued telomere
erosion may not allow tumors with shorter telomeres to
progress. Our results support this hypothesis by demonstrat-
ing continuous telomere shortening when there is lack of
telomere stabilization by telomerase activity or ALT.
In summary, our results have three important implications.
First, the correlation between lack of telomere maintenance
and telomere shortening in PLGG suggests that senescence
may play an important role in PLGG tumor evolution. Sec-
ond, our findings support the value of telomere maintenance
as an important prognostic factor in the management of
Figure 4. Time to last progression as a function of TRF length. Patients who
did not progress were designated as time to last progression = 0.
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PBT. Third, PLGG can serve as a model for the emerging
concept of tumor control, in which (when the tumor cell
cannot be killed) its mechanisms of immortality may be dis-
abled, making it susceptible to normal aging process, senes-
cence, and growth arrest.
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